Gravitate Health under the lens #1 | We present Gravitate Health

Dear reader,

We would like to welcome you to our newsletter and introduce Gravitate Health, a public – private partnership with 39 members from Europe and the US.
Gravitate Health’s mission is to equip and empower patients with digital health information and tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life.
Our project is co-led by University of Oslo and Pfizer, funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the EFPIA, and IMI2 Associated Partners.

The Gravitate Health design approach
One of the timeless rules of design says that “To design a great experience, you need to understand the user’s perspective.” We are aware that as intuitive as it may sound, that’s not always easy to implement when designing a solution or a product. Therefore, we in Gravitate Health decided to take the approach where the needs and wants of primary end-users in focus.
How do we do it? From the early beginning of the project we have ongoing conversations and creative efforts with the people who will interact with and use Gravitate Health solution. The first question posed to the users was “do you consider you have relevant information about your medication?”. Together we have been assessing challenges and concerns, “pain points” and “wishes”, our solution needs to take into account.
As a result, we have co-created Gravitate Health Personas, that demonstrate the dimensions that we can further elaborate and prototype in the testing scenarios. So, we bring this understanding into the development of the product by using human-centred design techniques and are keeping our User Advisor Group in the loop.

Our work is organised in 8 interlinked Work Packages (WPs) or Project Sections.
• The Operative WPs enable “Patient Voice-Human touch” through innovative and personalized interventions, a multi-faceted evaluation set-up as well as technological development and interoperability capabilities (WP1, WP2, WP3, WP4, WP6).
• The Transversal, supportive WPs include a communication and dissemination strategy, plans for sustainable exploitation and overall management and governance in the project (WP5, WP7, WP8).

Acknowledgement
Gravitate Health is an EU funded project which has received funding from the Innovative Medicines Initiative (IMI) with support from Horizon 2020 programme, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and IMI2 Associated Partner Datapharm Ltd.

Disclaimer
This communication reflects the views of the authors and neither the IMI nor the European Union, EFPIA, or Datapharm Limited are liable for any use that may be made of the information contained herein.